Peripheral Artery Disease in Menopause: The Circulation Risk Women Overlook

Peripheral artery disease (PAD) happens when arteries outside the heart — most often in the legs — narrow due to fatty plaque buildup, reducing blood flow to the muscles and tissue they supply. It's part of the same underlying process, atherosclerosis, that causes heart attacks and strokes, but because it shows up in the legs rather than the chest, it's frequently misread as an aging joint problem rather than a circulation problem.

Estrogen has a protective effect on blood vessels: it helps keep artery walls flexible, supports healthy cholesterol patterns, and reduces inflammation that contributes to plaque formation. As estrogen declines through perimenopause and into postmenopause, arteries become stiffer and more prone to plaque buildup, and other cardiovascular risk factors — blood pressure, LDL cholesterol, and blood sugar — tend to worsen at the same time. The combination is why PAD, like heart disease and stroke, shows a marked increase in risk after the menopause transition rather than a smooth, gradual rise with age alone.

More common than most women realize, and more common than in age-matched men. A 2026 global burden of disease analysis published in the *International Journal of Women's Health* estimated that postmenopausal women accounted for 66.4 million prevalent cases of lower extremity PAD worldwide in 2021 — representing 58.39% of all PAD cases globally. Between 1990 and 2021, prevalent cases, PAD-related deaths, and disability-adjusted life years all roughly doubled, increasing by 99.84%, 72.93%, and 73.06% respectively, driven mainly by population growth and an aging population rather than a rising rate of disease in any one person.

Notably, the analysis found postmenopausal women had higher PAD prevalence than age-matched men at every age group studied, even though women's age-standardized death and disability rates were somewhat lower individually. Because women live longer on average, the total burden of PAD-related death and disability in postmenopausal women is still greater in absolute numbers. Researchers project the burden will continue climbing — an estimated 38% increase in absolute cases by 2035 — even as standardized rates modestly decline with better prevention and treatment.

The same 2026 analysis broke down exactly which risk factors drive the most PAD burden in postmenopausal women, and the results line up closely with what's already known about heart disease risk after menopause. High fasting plasma glucose was the single largest contributor, responsible for 35.39% of the disease burden — a reminder that blood sugar control matters for circulation well before a diabetes diagnosis. Kidney dysfunction was the second-largest factor at 29.83%, followed by high body mass index (20.26%), high systolic blood pressure (13.21%), smoking (12.31%), and low physical activity (2.91%).

What's striking about this list is how much overlap it has with the risk factors already tracked for heart disease, stroke, and metabolic syndrome in menopause — meaning the same lifestyle and medical management priorities protect multiple vascular systems at once rather than requiring a separate approach for leg circulation specifically. It also explains why women managing type 2 diabetes, chronic kidney disease, or obesity going into menopause face a compounded risk that's worth flagging specifically with their clinician, rather than assuming leg symptoms are unrelated to their metabolic health.

The hallmark PAD symptom is called intermittent claudication: pain, cramping, heaviness, or fatigue in the calf, thigh, or buttock that reliably comes on with walking or climbing stairs and eases within minutes of resting. Because this pattern can resemble ordinary muscle fatigue, arthritis, or simple deconditioning, it's frequently attributed to "just getting older" rather than investigated as a circulation issue — especially in women, who are underdiagnosed with PAD relative to men despite having equal or higher rates of the disease.

Other signs worth mentioning to a clinician include feet or lower legs that feel persistently cold or look pale or bluish compared with the rest of the body, toenails that grow slowly or thicken, hair loss on the lower legs, and any wound or sore on the foot or ankle that's slow to heal. In more advanced PAD, pain can occur even at rest, particularly at night. None of these symptoms are exclusive to PAD, but the combination of exertional leg pain that eases with rest plus any of these other signs is worth raising proactively rather than waiting for it to be asked about.

The standard first-line test is the ankle-brachial index (ABI) — a quick, painless comparison of blood pressure measured at the ankle versus the arm using a regular blood pressure cuff and a small handheld Doppler device. A lower ratio at the ankle compared with the arm suggests reduced blood flow to the leg and can be measured in a standard primary care or vascular clinic visit in about 15 minutes.

If the ABI result is abnormal or borderline, or if symptoms strongly suggest PAD despite a normal ABI, your clinician may order additional imaging such as a Doppler ultrasound of the leg arteries to pinpoint the location and severity of any blockage. Given how underdiagnosed PAD is in women, it's reasonable to specifically ask for an ABI test if you have risk factors like diabetes, high blood pressure, a smoking history, or exertional leg symptoms, rather than assuming it will come up automatically during a routine visit.

Because the same risk factors drive PAD, heart disease, and stroke after menopause, managing them protects your circulation broadly rather than requiring PAD-specific interventions. Getting fasting glucose, blood pressure, and cholesterol checked and managed — through medication when needed, not just lifestyle change — addresses the three largest modifiable contributors identified in the risk-factor breakdown above. Quitting smoking specifically reduces PAD progression risk more than almost any other single change, since smoking directly damages the arterial lining.

Regular walking is both protective and, counterintuitively, part of the standard treatment for existing PAD — supervised walking programs are a first-line therapy that improves walking distance and symptoms over time by encouraging the body to develop small collateral blood vessels around narrowed arteries. For women also managing weight through a GLP-1 medication, it's worth knowing that the SELECT cardiovascular outcomes trial found semaglutide reduced major adverse cardiovascular events by 20% in people with existing heart disease and overweight or obesity — supporting the broader idea that treating metabolic risk factors together protects the whole vascular system, including circulation to the legs.